: Uniquely transitioned from a career in investment banking at Goldman Sachs to medicine, later graduating from Harvard Medical School .

: A leading figure in clinical trials for teprotumumab , an FDA-approved treatment for TED. Her work has characterized its efficacy in recalcitrant TED cases .

In an era of brand synergy, Wester remains defiantly analog. Her Instagram (managed, she has claimed, by a friend who just posts pictures of clouds) has no selfies, no “studio sale” posts, no earnest videos about her “process.” This absence is, paradoxically, her strongest curatorial move. By refusing to be a personality, Wester forces the audience to engage only with the work. In interviews, she is polite but evasive, often quoting Simone Weil or describing her fear of ceiling fans. This is not coyness; it is a philosophical stance. Wester believes that the artist should be a vessel , not a celebrity .

: Educates the public on the risks of eyelash extensions and how they can be applied safely. Long-term real world teprotumumab outcomes - IOVS

If her visual art is the shadow, her writing is the blade. Wester’s 2019 essay collection, “On Holding Things Wrong,” should be required reading for anyone who has ever felt like a fraud in their own skin. Unlike the aestheticized misery of social media poetry, Wester’s prose is clinical but bleeding. She writes about grief as a spatial problem, anxiety as a thermostat malfunction, and love as a “grammatical error we refuse to correct.”

Wester is regarded as a representative of the "New Journalism" in Sweden—reporting that prioritizes deep immersion and narrative storytelling over simple news reporting. She is frequently invited to participate in public debates and media panels, offering commentary on everything from press freedom to criminal justice reform.

Here is a write-up regarding her career and impact.

: Served in key leadership roles for Women in Ophthalmology (WIO) from 2018–2024 and advises for ACE Global. Key Contributions & Innovations